Applied DNA Sciences names Judy Murrah as new chairperson and CEO

STONY BROOK, NY - Applied DNA Sciences, Inc. (NASDAQ:APDN), a micro-cap company with a market value of $2.46 million, announced that Dr. James A. Hayward is retiring as Chairperson and Chief Executive Officer effective June 18, 2025, after 20 years with the company. According to InvestingPro analysis, the company appears undervalued against its Fair Value estimate.

The Board of Directors has appointed Judy Murrah to serve as Chairperson, Board Director, and Chief Executive Officer while retaining her current position as President. Murrah will lead the executive management team that includes Clay Shorrock, Chief Legal Officer and President of LineaRx, and Beth Jantzen, Chief Financial Officer. The leadership transition comes as the company faces challenging financial metrics, with revenue declining 31.3% in the last twelve months to $3.79 million.

Murrah brings over a decade of operational leadership at Applied DNA, where she has contributed to product commercialization and business scaling. Her previous experience includes leadership roles at Symbol Technologies, where she helped grow the company to approximately $2 billion in revenue, and later at Motorola following its acquisition of Symbol. She is credited as an inventor on 14 U.S. patents and holds an MBA from Harvard Business School.

Board Director Robert C. Catell acknowledged Dr. Hayward’s contributions, stating that his "accomplishments and impact are wide-ranging and will endure with the Applied DNA team and the local Long Island community."

Applied DNA Sciences specializes in PCR-based DNA technologies, operating in two business markets: enzymatic manufacture of synthetic DNA for nucleic acid-based therapeutics and detection of DNA and RNA in molecular diagnostics and genetic testing services. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 4.45, though its overall financial health score remains weak at 1.39. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

The information in this article is based on a company press release statement.

In other recent news, Applied DNA Sciences has successfully regained compliance with the Nasdaq’s minimum bid price requirement. The company confirmed that its stock maintained a closing bid price of at least $1.00 per share for 16 consecutive business days, resolving a previous notification of non-compliance. This achievement allows Applied DNA Sciences to continue its listing on the Nasdaq, ensuring visibility and accessibility to investors. In addition, the company has secured a U.S.-based supply chain for essential materials through its subsidiary, LineaRx, aligning with the BIOSECURE Act of 2024. This move is expected to enhance its position in the genetic medicines market, particularly for mRNA/DNA products. Furthermore, Applied DNA Sciences has scheduled its 2025 Annual Meeting of Stockholders for May 22, which will be held virtually. Stockholders are reminded of the April 11 deadline for submitting proposals for inclusion in the proxy materials. Lastly, the company is facing a Nasdaq delisting notice due to a previous failure to meet the minimum bid price rule, but it has requested a hearing to address the issue.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.